HomeCompareGIFX vs JNJ

GIFX vs JNJ: Dividend Comparison 2026

GIFX yields 18181.82% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GIFX wins by $20382968138483965952.00M in total portfolio value
10 years
GIFX
GIFX
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20382968138483965952.00M
Annual income
$20,164,798,479,641,134,000,000,000.00
Full GIFX calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — GIFX vs JNJ

📍 GIFX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGIFXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GIFX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GIFX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GIFX
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$17,140,078,707,694,964,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, GIFX beats the other by $17,140,078,707,694,964,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GIFX + JNJ for your $10,000?

GIFX: 50%JNJ: 50%
100% JNJ50/50100% GIFX
Portfolio after 10yr
$10191484069241982976.00M
Annual income
$10,082,399,239,820,567,000,000,000.00/yr
Blended yield
98.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GIFX
No analyst data
Altman Z
2743.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GIFX buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGIFXJNJ
Forward yield18181.82%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$20382968138483965952.00M$30.3K
Annual income after 10y$20,164,798,479,641,134,000,000,000.00$4,689.40
Total dividends collected$20368560651224936448.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GIFX vs JNJ ($10,000, DRIP)

YearGIFX PortfolioGIFX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$1,828,882$1,818,181.82$10,592$272.30+$1.82MGIFX
2$312,726,966$310,770,062.56$11,289$357.73+$312.72MGIFX
3$49,997,862,140$49,663,244,286.24$12,123$472.89+$49997.85MGIFX
4$7,474,070,205,933$7,420,572,493,443.65$13,141$629.86+$7474070.19MGIFX
5$1,044,712,232,322,833$1,036,714,977,202,484.10$14,408$846.81+$1044712232.31MGIFX
6$136,547,911,758,351,100$135,430,069,669,765,680.00$16,021$1,151.60+$136547911758.34MGIFX
7$16,689,313,388,956,088,000$16,543,207,123,374,653,000.00$18,122$1,588.22+$16689313388956.07MGIFX
8$1,907,542,220,817,720,100,000$1,889,684,655,491,537,200,000.00$20,930$2,228.20+$1907542220817720.25MGIFX
9$203,896,877,423,206,970,000,000$201,855,807,246,932,000,000,000.00$24,792$3,191.91+$203896877423206976.00MGIFX
10$20,382,968,138,483,967,000,000,000$20,164,798,479,641,134,000,000,000.00$30,274$4,689.40+$20382968138483965952.00MGIFX

GIFX vs JNJ: Complete Analysis 2026

GIFXStock

GIFA, Inc., through its subsidiaries, provides financial services and consultancy, brokerage, business loans, project funding, crowdfunding advice, and consultancy to individual and corporate clients. It also offers personal and professional business development and investment advice to private clients; and cargo transportation and logistics, shipping and chartering, airline representation, and corporate and leisure travel services. In addition, the company provides end-to-end supply and demand chain management services engaging in controlling and coordinating supply of materials to a range of entities that are involved in producing and delivering goods and services. Further, it engages in media business comprising newspaper and Webtv; provides consultancy, advice, assistance, and support for local businesses, as well as opportunity to access international finance; and offers local businesses and individuals small loans. The company was formerly known as Firefish, Inc. and changed its name to GIFA, Inc. in October 2017. GIFA, Inc. was founded in 2008 and is headquartered in Lefkosa, Cyprus.

Full GIFX Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GIFX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GIFX vs SCHDGIFX vs JEPIGIFX vs OGIFX vs KOGIFX vs MAINGIFX vs ABBVGIFX vs MRKGIFX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.